Botulinum Toxin Market Research Report - Global Forecast till 2025

Global Botulinum Toxin Market: Information by Type (Botulinum Toxin A and Botulinum Toxin B), Application (Aesthetic and Therapeutic), End User (Dermatology Centers, Hospitals and Clinics and others) and Region (Americas, Europe, Asia-Pacific, and the Middle East & Africa) - Forecast till 2025

ID: MRFR/HC/7095-CR | January 2020 | Region: Global | 151 pages

Market Overview


Botulinum Toxin Market is expected to register a CAGR of 10.3% to reach USD 9442.93 Million by 2025.


The global botulinum toxin market is expected to exhibit lucrative growth during the forecast period. One of the significant factors characterizing the market growth is the surge in demand for facial aesthetics. However, the adverse effects associated with botulinum toxin and poor reimbursement policies is anticipated to limit market growth over the forecast period.


Market Dynamics


Botulinum toxin is an exotoxin released by the organism Clostridium botulinum responsible for the deadly poisoning condition known as botulism. The botulinum neurotoxins include eight distinct subtypes identified as A, B, C1, C2, D, E, F, and G. Botulinum toxin is widely preferred as an effective mode of treatment across cosmetic and various therapeutic indications such as spasticity, cervical dystonia, and chronic migraine, etc.


The growing cases of spasticity, cervical dystonia, and chronic migraine, a surge in demand for facial aesthetics, and rising product launches and approvals are likely to drive the growth of the global botulinum toxin market during the forecast period.


For instance, in March 2018, Merz Pharma GmbH & Co. KGaA, a German-based aesthetics and neurotoxin company, received US FDA approval for supplemental biologics license application (SBLA) for Xeomin (Incobotulinumtoxina) to treat sialorrhea in adult patients.


Global Botulinum Toxin Market Share, by Application, 2018 & 2025 (USD Million)
 Botulinum Toxin Market


Source: MRFR Analysis


Segmentation


On the basis of type, the Global Botulinum Toxin Market has been classified into botulinum toxin type A and B. Botulinum toxin type A products are likely to hold a maximum market share of 96.29% during the forecast period. The majority of the products available in the market are botulinum toxin type A products. Botox (Allergan PLC), Dysport (Galderma SA), and Xeomin (Merz Pharma GmbH & Co KGaA) are leading brands of botulinum toxin A type which is holding significant market share in the global market.


Based on Application, the global botulinum toxin market has been divided into therapeutic and aesthetic applications. The therapeutic segment is further classified into a chronic migraine, spasticity, cervical dystonia, overactive bladder, blepharospasm, and others.


By End User, the market has been segmented into dermatology Centers, Hospitals & Clinics, and others.


Global Botulinum Toxin Market Share, 2018 (%)
 Botulinum Toxin Market


Source: MRFR Analysis


Regional Analysis


The Global Botulinum Toxin Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The global botulinum toxin market in the Americas is segmented into North America and Latin America. In this region, North America is expected to dominate the market.


The Americas is expected to command the largest market share due to owing to the increasing product approvals, rising cases of spasticity, and the presence of major manufacturers such as US WorldMeds, LLC., Evolus, Inc., Hugel, Inc., and Revance Therapeutics, Inc. in the region. Additionally, increasing product approvals and rising incidence of spasticity are likely to drive the growth of the botulinum toxin market in these countries. In August 2019, US WorldMeds, LLC, a US-based pharmaceutical company, received US FDA approval for the supplemental biologics license application for Myobloc (rimabotulinumtoxinB) injection for the treatment of chronic sialorrhea.


The European Botulinum Toxin market comprises Eastern Europe and Western Europe. Western Europe comprises countries such as Germany, the UK, France, Italy, and Spain. Europe accounts for the second-largest market for global aesthetics owing to the rising botulinum toxin procedures and the presence of developed economies such as Germany, the UK, and France. According to the International Society of Aesthetic Plastic Surgery, around 321,702 botulinum toxin procedures were carried out in Germany in 2018.


The Asia-Pacific is expected to exhibit the fastest market growth from 2019 to 2025 owing to the growing geriatric population, rising per capita disposable income, developing healthcare infrastructure, medical tourism, and booming entertainment industry. In India, according to a report published by United Nations Population Fund (UNFPA), the share of the population over the age of 60 was 8% in 2015, and it is expected to reach 19% by 2050. This regional market is expected to grow at a CAGR of 11.01% during the forecast period of 2019 to 2025.


The Middle East & Africa is anticipated to hold the lowest market share in the global botulinum toxin market. In this region, the Middle East is expected to dominate the market, owing to the presence of a well-developed healthcare sector. The growth of the market is majorly attributed to the owing to the presence of countries such as Kuwait, Qatar, Oman, and South Arabia and high healthcare spending.


Key Players


The Prominent Players in the Global Botulinum Toxin Market are Allergan PLC, Merz Pharma GmbH & Co KGaA, Galderma S.A., Daewoong Pharmaceutical Co., Ltd, Ipsen Pharma, US WorldMeds, LLC. (Solstice Neurosciences, LLC), Evolus, Inc., Hugel, Inc, Medytox, Revance Therapeutics, Inc.


Some of the key strategies followed by players operating in the global botulinum toxin market were innovation, new product launches, and acquisition & mergers.



  • In September 2019, Medytox launched Coretox, a botulinum toxin product with reduced the risk of resistance to extend its product portfolio



  • In September 2019, Ipsen Pharma announced FDA approval for Dysport (abobotulinumtoxinA) for the treatment of lower limb spasticity in pediatric patients of age group 2 to 17. This approval is expected to boost the sales of botulinum toxin in the market



  • In March 2018, The US FDA approved the supplemental biologics license application (SBLA) for Merz Pharma GmbH & Co KGaA product Xeomin (Incobotulinumtoxina) to treat sialorrhea in adult patients


Market Segmentation


Global Botulinum Toxin Market, by Type



  • Botulinum Toxin Type A

  • Botulinum Toxin Type B


Global Botulinum Toxin Market, by Application



  • Therapeutic

    • Chronic Migraine

    • Spasticity

    • Cervical Dystonia

    • Overactive Bladder

    • Blepharospasm

    • Others



  • Aesthetics


Global Botulinum Toxin Market, by End User



  • Dermatology Centers

  • Hospitals & Clinics

  • Others


Global Botulinum Toxin Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America





  • Europe

    • Western Europe

      • Germany

      • UK

      • France

      • Italy

      • Spain

      • Rest of Western Europe



    • Eastern Europe





  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific





  • Middle East & Africa

    • Middle East

    • Africa




Available Additional Customizations



  • Company Profiles of Other Key Players

  • Botulinum Toxin Market, Industry Trends

  • Investment Opportunities


Intended Audience



  • Botulinum toxin product manufacturing companies

  • Research & development organizations

  • Academic institutes



Frequently Asked Questions (FAQ) :


The valuation was USD 4119 million in 2018.

The better expansion scope is for the aesthetic segment.

The hospitals segment has the market lead.